Source link : https://www.newshealth.biz/health-news/once-weekly-insulin-looks-good-in-t2d-but-risk-seen-in-t1d/
MADRID, Spain — Eli Lilly’s investigational once-weekly basal insulin analog efsitora alfa continues to show noninferiority to once-daily insulin in people with type 2 diabetes. However, in those with type 1 diabetes, there was an increased risk for hypoglycemia. The data come from Lilly’s QWINT global phase 3 clinical trial program for efsitora alfa, which […]
Author : News Health
Publish date : 2024-09-11 11:34:49
Copyright for syndicated content belongs to the linked Source.